PAREXEL International Corp

PAREXEL International — J.P. Morgan Healthcare Conference 2014

28 slides from PAREXEL International's conference presentation, Jan 13, 2014

  1. Slide 1: PAREXEL JP Morgan Healthcare Conference January 15, 2014

    © 2014 PAREXEL International PAREXEL JP Morgan Healthcare Conference January 15, 2014

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding future results and events, including, without limitation, statements regarding th

  3. Slide 3: Agenda

    Agenda Introducing PAREXEL Market Environment Growth Strategy Profitability Improvement Strategies Outlook

  4. Slide 4: Strongly Positioned in a Growing Market

    Strongly Positioned in a Growing Market  Top-3 publicly-traded biopharmaceutical services company – strong brand  Integrated clinical research, consulting and technology service offering  Extensive global footprint – 77 locations, 51 countries  FY’13 revenue $1.7B; Q1 record backlog of $4.6B  P

  5. Slide 5: Differentiated Set of Services

    Differentiated Set of Services  Clinical Research Services – Phase I-IV clinical development and logistics  PAREXEL Consulting and Medical Communications Services – consulting in product development, medical communications, and commercialization  Perceptive Informatics – leading eClinical solutio

  6. Slide 6: Broad Expertise and Client Base

    Broad Expertise and Client Base  Supporting over 1,700 clinical projects in 20 therapeutic areas  Work with all of the Top 50 biopharma- ceutical and Top 10 biotech companies Representative Clients Outlook Profitability Improvement Strategies Growth Strategy Market Environment Introducing PAREXEL

  7. Slide 7: Outsourcing Increasing, Global CROs Increasing Share

    Outsourcing Increasing, Global CROs Increasing Share  R&D growing in low single digits  Outsourcing penetration rates increasing  “State-of-the-Art” for clinical development resides in CROs  Client restructurings can lead to more outsourcing  Top 7 CROs soon to exceed 50% market share * Source:

  8. Slide 8: Strategic Partnerships Represent an Increasing Percentage of All Development Activity

    Strategic Partnerships Represent an Increasing Percentage of All Development Activity 58% 42% 2012 All Other Strategic Partnerships $27B 76% 24% 2009 $17B *Source: PAREXEL Analysis (Phases I - IV) Biopharma Industry Clinical Development Outsourcing Dollars* Outlook Profitability Improvement Strategi

  9. Slide 9: Growing Importance of Emerging Countries

    Growing Importance of Emerging Countries  ~70% of growth generated by “Pharmerging” markets  Speed of recruitment  Cost advantages  Market opportunity  Global footprint critical success factor for PAREXEL * IMS Institute for Health Informatics, “The Global Use of Medicines: Outlook Through 2015

  10. Slide 10: Technology Solutions of Increasing Importance to Clients

    Technology Solutions of Increasing Importance to Clients  Strong client interest in integrated “eClinical Suite” capabilities  Specialized applications solve specific problems (e.g. LIQUENT acquisition – 12/2012) Outlook Profitability Improvement Strategies Growth Strategy Market Environment Intro

  11. Slide 11: Biotech Funding Up; SEBPCOs Growing in Importance

    Biotech Funding Up; SEBPCOs* Growing in Importance  80%+ of pipeline projects originate from SEBPCOs**  42% of 2012 NME approvals by first-time sponsors  Virtual companies require CRO expertise Chart Source: Yahoo Finance * SEBPCOs = Small and Emerging Biopharmaceutical Companies ** Source: Pharm

  12. Slide 12: Clinical Research Services Growth Strategy

    Clinical Research Services Growth Strategy  Enter into new strategic partnerships  Pursue additional Early Product Development opportunities  Focus on small & mid-sized accounts - Biopharm Unit  Expand PACE, Clinical Logistics, and Functional Services businesses Outlook Profitability Improvement

  13. Slide 13: PAREXEL Consulting and Medical Communications Growth Strategy

    PAREXEL Consulting and Medical Communications Growth Strategy Accelerate growth of Commercialization Services Capitalize on the increased outsourcing of Regulatory Affairs Additional M&A (e.g. HERON acquisition) Outlook Profitability Improvement Strategies Growth Strategy Market Environment Introduc

  14. Slide 14: Perceptive Informatics Growth Strategy

    Perceptive Informatics Growth Strategy  Add new applications to Perceptive MyTrials™  Leverage PAREXEL  Drive business with other software providers & CROs  Additional M&A Outlook Profitability Improvement Strategies Growth Strategy Market Environment Introducing PAREXEL

  15. Slide 15: Targeted M&A – String of Pearls Approach

    Targeted M&A – “String of Pearls” Approach PAREXEL M&A Evolution Global Financial Crisis Actively Acquire Businesses Actively Assess and Complete Deals Actively Seeking Opportunities 2006 2007 2008 2009 2010 2011 2012 Pre- 2006 2013 2014 and beyond LIQUENT APEX ClinPhone HERON CCT 1988 - 2005: 32 tr

  16. Slide 16: Strong Backlog Growth

    Strong Backlog Growth FY'09 FY'10 FY'11 FY'12 FY'13 $2,176 $2,681 $3,444 $4,394 $4,609 D o ll a rs i n M il li o n s Backlog Outlook Profitability Improvement Strategies Growth Strategy Market Environment Introducing PAREXEL

  17. Slide 17: Continued Margin Improvement Key Focus for FY'14 and Beyond

    Continued Margin Improvement Key Focus for FY’14 and Beyond * Adjusted numbers which exclude the impact of special items as detailed in the Appendix to this presentation. E = Estimate as discussed in 1/15/14 webcast $0 $100 $200 $300 $400 FY'12 FY'13 FY'14E O I ($ M ) PAREXEL Operating Income / Marg

  18. Slide 18: Building Blocks of Operating Margin Expansion

    Building Blocks of Operating Margin Expansion Operating Margin Expansion Gross margin expansion in CRS Leverage benefits of Strategic Partnerships Leverage SG&A infrastructure across SBUs IT driven process efficiencies Efficient service functions Performance culture Economies of scale in Perceptive

  19. Slide 19: Gross Margin Expansion in CRS

    Gross Margin Expansion in CRS Increasing Productivity & Billability  Reduction of managerial layers, increased span of control  Simplification of role definitions and workflow  Improve labor mix  Optimize staffing demand and supply  Consolidate back-office and support functions to shared servic

  20. Slide 20: Economies of Scale in Perceptive

    Economies of Scale in Perceptive Scaling the Business  Expansion of eClinical cloud offerings  Further enrich technology revenue mix with added service components  Leverage technology platform for integrated data delivery Productivity & Operational Execution  Increase usage of low cost countries

  21. Slide 21: Leverage Low Cost Locations & Shared Service Centers

    Leverage Low Cost Locations & Shared Service Centers  India - major back office hub for all business units and functions  Regional satellite hubs  Proximal expertise to clients and trial sites 0 50 100 150 200 250 300 350 FY'10 FY'11 FY'12 FY'13 Dec '13 India Headcount (Indexed) Outlook Profitabi

  22. Slide 22: Driving Service Functions Towards Higher Efficiency

    22 Driving Service Functions Towards Higher Efficiency  Further consolidate IT infrastructure  Simplify IT application footprint  Cost effective application support IT  Extend scope of shared services  Centers of expertise leverage knowledge x- business units Finance  Extend scope of shared se

  23. Slide 23: Financial Strategies Drive EPS Growth

    Financial Strategies Drive EPS Growth Outlook Profitability Improvement Strategies Growth Strategy Market Environment Introducing PAREXEL

  24. Slide 24: Continue to Drive Solid Revenue Growth and Margin Expansion

    Continue to Drive Solid Revenue Growth and Margin Expansion FY'10 FY'11 FY'12 FY'13 FY'14E $1,131 $1,212 $1,397 $1,734 $1,895 - $1,925 D o ll a rs In M il li o n s Revenue Growth 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% FY'09 FY'10 FY'11 FY'12 FY'13 FY'14E 8.6% 9.1% 7.4% 6.8% 8.0% 9.7% Operating Margin

  25. Slide 25: Creating Shareholder Value Through Profitable Growth

    Creating Shareholder Value Through Profitable Growth * Adjusted numbers which exclude impact of special, restructuring or other charges as detailed in the Appendix to this presentation E = Estimate and EPS guidance issued in a press release dated 1/13/14 Return on Invested Capital (ROIC) = Adjusted

  26. Slide 26: Long-term Financial Goals

    Long-term Financial Goals  10%- 12% revenue growth target  12-14% operating margin  Double-digit multi-year EPS growth  Continued growth in our ROIC Outlook Profitability Improvement Strategies Growth Strategy Market Environment Introducing PAREXEL

  27. Slide 27: Appendix

    APPENDIX SLIDE

  28. Slide 28: Reconciliation of Non-GAAP Financial Measures

    Reconciliation of Non-GAAP Financial Measures *Dollars in thousands, Fiscal Year ends June 30. FY 2009 FY 2010 FY 2011 FY 2012 FY 2013 Selling, General and Administrative (1) -$ 4,250$ 560$ 4,027$ 81$ (7) Depreciation (2) -$ 450$ Other (Benefit) Charges (3) 15,000$ (1,144)$ -$ -$ -$ Restructuring Ex

PAREXEL International — J.P. Morgan Healthcare Conference 2014 on 6ix